PURPOSE: Prognostic comparison of phosphohistone-H3 (PPH3) with Cytokeratin 5/6 and/or 14 positive (=basal-CK), triple (ER, PR, HER2)-negative (=TNP) and basal-like (=TNP and basal-CK positive) phenotype in invasive breast cancers. PATIENTS AND METHODS: Classical variables, PPH3, ER, PR, basal-CK and HER2 in 240 T1-2N0M0 patients under 71 years. RESULTS: TNP and basal-like cancers had higher PPH3 expression than the other cancers (mean 48 versus 11, P<0.001). Fifteen percent of the patients in the whole group, but 32-38% of TNP and basal-like cancers recurred. With multivariate analysis, PPH3<13 (n=156) versus >or=13 (n=84=35% of all cases) was the strongest and only prognosticator (10-year survival 96% and 64%, P<or=0.001, Hazard ratio=9.0). CONCLUSION: PPH3 is the strongest prognosticators in luminal, Triple negative and basal-like T1-2N0M0 invasive breast cancers.
PURPOSE: Prognostic comparison of phosphohistone-H3 (PPH3) with Cytokeratin 5/6 and/or 14 positive (=basal-CK), triple (ER, PR, HER2)-negative (=TNP) and basal-like (=TNP and basal-CK positive) phenotype in invasive breast cancers. PATIENTS AND METHODS: Classical variables, PPH3, ER, PR, basal-CK and HER2 in 240 T1-2N0M0 patients under 71 years. RESULTS: TNP and basal-like cancers had higher PPH3 expression than the other cancers (mean 48 versus 11, P<0.001). Fifteen percent of the patients in the whole group, but 32-38% of TNP and basal-like cancers recurred. With multivariate analysis, PPH3<13 (n=156) versus >or=13 (n=84=35% of all cases) was the strongest and only prognosticator (10-year survival 96% and 64%, P<or=0.001, Hazard ratio=9.0). CONCLUSION:PPH3 is the strongest prognosticators in luminal, Triple negative and basal-like T1-2N0M0 invasive breast cancers.
Authors: Kristin Jonsdottir; Susanne R Janssen; Fabiana C Da Rosa; Einar Gudlaugsson; Ivar Skaland; Jan P A Baak; Emiel A M Janssen Journal: PLoS One Date: 2012-11-07 Impact factor: 3.240
Authors: Manish V Bais; Matthew A Nugent; Danielle N Stephens; S Selva Sume; Kathrin H Kirsch; Gail E Sonenshein; Philip C Trackman Journal: PLoS One Date: 2012-02-08 Impact factor: 3.240
Authors: Krzysztof Symonowicz; Kamila Duś-Szachniewicz; Marta Woźniak; Marek Murawski; Paweł Kołodziej; Beata Osiecka; Kamil Jurczyszyn; Piotr Ziółkowski Journal: Exp Ther Med Date: 2014-07-16 Impact factor: 2.447
Authors: Tone Hoel Lende; Marie Austdal; Anne Elin Varhaugvik; Ivar Skaland; Einar Gudlaugsson; Jan Terje Kvaløy; Lars A Akslen; Håvard Søiland; Emiel A M Janssen; Jan P A Baak Journal: BMC Cancer Date: 2019-11-08 Impact factor: 4.430
Authors: Marie Klintman; Carina Strand; Cecilia Ahlin; Sanda Beglerbegovic; Marie-Louise Fjällskog; Dorthe Grabau; Einar Gudlaugsson; Emiel A M Janssen; Kristina Lövgren; Ivar Skaland; Pär-Ola Bendahl; Per Malmström; Jan P A Baak; Mårten Fernö Journal: PLoS One Date: 2013-12-04 Impact factor: 3.240